Product Image
Please see full prescribing and safety information, including boxed warning, for LEVOFLOXACIN vials and premix bags. LEVOFLOXACIN Package Insert vials | premix bags LEVOFLOXACIN Medication Guide vials | premix bags

Available in:

  • 250 mg per 50 mL in 5% Dextrose premix bags**
  • 500 mg per 100 mL in 5% Dextrose premix bags**
  • 750 mg per 150 mL in 5% Dextrose premix bags**
  • 500 mg per 20 mL single-use vials
  • 750 mg per 30 mL single-use vials

Benefits:

  • AP Rated
  • Preservative-free
  • Not made with natural rubber latex
  • **DEHP-free
  • **PVC-FREE

LEVOFLOXACIN Injection in 5% Dextrose and LEVOFLOXACIN Injection*

Brand Name Equivalent: LEVAQUIN® (LEVAQUIN is a registered trademark of Daiichi Sankyo Company.)
Therapeutic Category: Anti-Infective / Antibiotic

PreventIV MeasuresSM Features:

  • Easy-to-read drug name and strengths printed on vials, cartons, bags and front and back of overwraps
  • Bar codes on vials, cartons and overwraps for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
  • Ready-to-use premix bags facilitate adherence to USP
NDC
#25021
Description Strength Fill
Volume
Concentration Container
Size
Closure Unit
of Sale
132-81 Premix Bag** 250 mg 50 mL 5 mg per mL N/A N/A 24
132-82 Premix Bag** 500 mg 100 mL 5 mg per mL N/A N/A 24
132-83 Premix Bag** 750 mg 150 mL 5 mg per mL N/A N/A 24
130-20 Glass Vial 500 mg 20 mL 25 mg per mL 20 mL 20 mm 1
130-30 Glass Vial 750 mg 30 mL 25 mg per mL 30 mL 20 mm 1

**DEHP-free and PVC-free

WARNING Fluoroquinolones, including LEVOFLOXACIN INJECTION in 5% dextrose and LEVOFLOXACIN INJECTION, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants [See Warnings and Precautions (5.1)].
Fluoroquinolones, including LEVOFLOXACIN INJECTION in 5% dextrose and LEVOFLOXACIN INJECTION, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid LEVOFLOXACIN INJECTION in 5% dextrose and LEVOFLOXACIN INJECTION in patients with a known history of myasthenia gravis [See Warnings and Precautions (5.2)]